PMID- 22185030
OWN - NLM
STAT- MEDLINE
DCOM- 20120120
LR  - 20111221
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 83
IP  - 10
DP  - 2011
TI  - [Antiplatelet drugs and gastrointestinal disorders: when and how effective are 
      inhibitors of proton pump?].
PG  - 68-71
AB  - Antiplatelet drugs are essential in current treatment of coronary heart disease 
      (CHD) but they have an adverse action--damage to gastrointestinal mucosa. 
      Long-term administration of several medicines in CHD patients makes possible 
      interaction of some drugs. Clinical trials show that proton pump inhibitors (PPI) 
      reduce frequency of recurrent gastrointestinal bleedings in patients of high 
      cardiological risk on antiplatelet therapy. In prescription of PPI to CHD 
      patients at high risk of gastropathy, it is necessary to consider both efficacy 
      and safety of the drug.
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Coronary Disease/blood/complications/drug therapy
MH  - Gastrointestinal Hemorrhage/blood/*chemically induced
MH  - Humans
MH  - Intestinal Mucosa/drug effects/pathology
MH  - Platelet Aggregation Inhibitors/*adverse effects/blood/*therapeutic use
MH  - Proton Pump Inhibitors/*adverse effects/blood/*therapeutic use
EDAT- 2011/12/22 06:00
MHDA- 2012/01/21 06:00
CRDT- 2011/12/22 06:00
PHST- 2011/12/22 06:00 [entrez]
PHST- 2011/12/22 06:00 [pubmed]
PHST- 2012/01/21 06:00 [medline]
PST - ppublish
SO  - Ter Arkh. 2011;83(10):68-71.